<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02655016</url>
  </required_header>
  <id_info>
    <org_study_id>213359</org_study_id>
    <secondary_id>PR-30-5017-C</secondary_id>
    <nct_id>NCT02655016</nct_id>
  </id_info>
  <brief_title>A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tesaro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Network of Gynaecological Oncological Trial Groups (ENGOT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Myriad Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tesaro, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a double-blind, randomized, placebo-controlled (2:1 niraparib:placebo) study in
      patients with Stage III or IV ovarian cancer. Patients must have completed front-line
      platinum based regimen with a physician-assessed response of Complete Response (CR) or
      Partial Response (PR). Additionally, patients must have a normal or &gt;90% decrease in cancer
      antigen 125 (CA-125) following front-line platinum treatment. The study will assess the
      efficacy of niraparib as maintenance treatment, as measured by PFS.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 7, 2016</start_date>
  <completion_date type="Anticipated">March 29, 2024</completion_date>
  <primary_completion_date type="Actual">May 17, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 34 months</time_frame>
    <description>Progression free survival was defined as the time from the date of treatment randomization to the date of first documentation of disease progression or death due to any cause in the absence of documented progression, whichever occurs first. It was assessed by the blinded independent central review (BICR). Median and 95% confidence interval (CI) are presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 34 months</time_frame>
    <description>Overall survival was defined as the time from the date of randomization to the date of death by any cause. Median and 95% CI are presented for overall survival interim analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Subsequent Therapy (TFST)</measure>
    <time_frame>Up to 34 months</time_frame>
    <description>Time to first subsequent therapy was defined as the time from the date of randomization to the date of the first subsequent anti-cancer therapy or death, whichever occurs first. Median and 95% CI are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival-2 (PFS2)</measure>
    <time_frame>Up to 34 months</time_frame>
    <description>PFS2 was defined as the time from the date of randomization to the date of progression on the next anti-cancer therapy following study treatment or death by any cause, whichever occurs first. Median and 95% CI are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant Reported Outcome (PRO): Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI)</measure>
    <time_frame>Baseline (Day 1, Pre-dose) and Up to Week 24</time_frame>
    <description>FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants responded to their symptom experience over the past 7 days using a 5-point Likert scale scored from &quot;not at all&quot; (0) to &quot;very much&quot; (4). FOSI score was calculated as (sum of item scores)*8 divided by (number of items answered). The FOSI score ranged from 0 (severely symptomatic) to 32 (asymptomatic). A higher score indicated a better quality of life (QoL). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PRO: European Quality of Life Scale, 5-dimensions, 5-levels of Severity (EQ-5D-5L) Utility Score</measure>
    <time_frame>Baseline (Day 1, Pre-dose) and Up to Week 24</time_frame>
    <description>The EQ-5D-5L is a well-validated general preference-based, health-related QoL instrument. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Scales of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)</measure>
    <time_frame>Baseline (Day 1, Pre-dose) and Up to Week 24</time_frame>
    <description>EORTC-QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale (global health status, QoL), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty) assessing additional symptoms commonly reported by participants with cancer. Five functional scales had total 15 items (physical-5, role-2, cognitive-4, emotional-2, and social-2). Each functional scales score was calculated by averaging scores of all scale items and transforming average scores linearly (1 minus [average score minus 1] divided by 3*100). All of the functional scales range in score from 0 to 100. Higher score represents a higher (&quot;better&quot;) level of functioning. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Global Health Status/QoL of EORTC-QLQ-C30</measure>
    <time_frame>Baseline (Day 1, Pre-dose) and Up to Week 24</time_frame>
    <description>EORTC-QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale (global health status, QoL), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty) assessing additional symptoms commonly reported by participants with cancer. A global health status/QoL scale had total 2 items. Each global health status/QoL scales score was calculated by averaging scores of all scale items and transforming average scores linearly ([average score minus 1] divided by 6*100). The global health status/QoL scales range in score from 0 to 100. Higher score represents a higher (&quot;better&quot;) level of health status/QoL. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Symptoms Scales and Symptoms Items (Dyspnea, Appetite Loss, Insomnia, Constipation, Diarrhea and Financial Difficulty) of EORTC-QLQ-C30</measure>
    <time_frame>Baseline (Day 1, Pre-dose) and Up to Week 24</time_frame>
    <description>EORTC-QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale, and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty) assessing additional symptoms commonly reported by participants with cancer. Symptom scale had total 7 items (fatigue-3, pain-2, nausea/vomiting-2). Each symptoms scales and 6 single additional symptoms items score was calculated by averaging scores of all scale items and transforming average scores linearly ([average score minus 1] divided by 3*100). All of the symptoms scales and 6 single additional symptoms scales range in score from 0 to 100. Higher score represents a higher (&quot;worse&quot;) level of symptoms. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Scales of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Ovarian Cancer Module (EORTC-QLQ-OV28)</measure>
    <time_frame>Baseline (Day 1, Pre-dose) and Up to 34 months</time_frame>
    <description>EORTC-QLQ-OV28 is supplement to EORTC-QLQ-C30. It includes 3 functional scales (body image, sexuality, attitude to disease/treatment) and 5 symptom scales/items (abdominal/gastrointestinal [GI] symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side-effects, and hair loss). Functional scales score (body Image and attitude to disease/treatment) was calculated by averaging scores of all scale items and transforming average scores linearly (1 minus [average score minus 1] divided by 3*100). Functional scales score (sexuality) was calculated by averaging scores of all scale items and transforming average scores linearly ([average score minus 1] divided by 3*100). All of the functional scales range in score from 0 to 100. Higher score represents a higher (&quot;better&quot;) level of functioning. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Symptoms Scale of EORTC-QLQ-OV28</measure>
    <time_frame>Baseline (Day 1, Pre-dose) and Up to 34 months</time_frame>
    <description>EORTC-QLQ-OV28 is supplement to EORTC-QLQ-C30. It includes 3 functional scales (body image, sexuality, attitude to disease/treatment) and 5 symptom scales/items (abdominal/GI symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side-effects, and hair loss). Symptoms scales score was calculated by averaging scores of all scale items and transforming average scores linearly ([average score minus 1] divided by 3*100). All of the symptoms scales range in score from 0 to 100. Higher score represents a higher (&quot;worse&quot;) level of symptoms. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Any Non-serious Adverse Event (Non-SAE) or Any SAE</measure>
    <time_frame>Up to 34 months</time_frame>
    <description>An adverse event is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.</description>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Curve (AUC) From 0 to the Last Quantifiable Concentration (AUC[0-last])</measure>
    <time_frame>Up to 34 months</time_frame>
    <description>Blood samples were planned to be collected for assessment of AUC(0-last).</description>
  </other_outcome>
  <other_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Up to 34 months</time_frame>
    <description>Blood samples were planned to be collected for assessment of Cmax.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Positive HRD Test</measure>
    <time_frame>Up to 34 months</time_frame>
    <description>Number of participants with positive HRD test was planned to be assessed.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">733</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Niraparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered once daily continuously during a 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered once daily continuously over a 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niraparib</intervention_name>
    <description>Niraparib vs Placebo 2:1 ratio</description>
    <arm_group_label>Niraparib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Patient must have histologically confirmed, advanced (FIGO Stage III or IV) high-grade
             predominantly serous or endometrioid ovarian cancer, fallopian tube cancer, or primary
             peritoneal cancer who have completed first line platinum based chemotherapy
             (neoadjuvant or adjuvant)

          -  Patient must have clinical complete response or partial response following completion
             of chemotherapy course.

          -  All Stage IV patients are eligible, irrespective of residual disease, after primary or
             interval debulking. Stage III patients are required to have visible residual disease
             after primary surgery. Patients with inoperable Stage III and IV disease are eligible

          -  Patient must agree to undergo central tumor HRD testing

          -  Patients of childbearing potential must have negative pregnancy serum test within 72
             hours of being dosed

          -  Patient must be randomized within 12 weeks of the first day of the last cycle of
             chemotherapy

        Main Exclusion Criteria:

          -  Patient has mucinous or clear cell subtypes of epithelial ovarian cancer,
             carcinosarcoma or undifferentiated ovarian cancer

          -  Patient has undergone more than 2 debulking surgeries

          -  Patient is to receive bevacizumab as maintenance treatment

          -  Patient is pregnant, breastfeeding, or expecting to conceive children, while receiving
             study treatment and for 180 days after the last dose of study treatment

          -  Patient has had prior treatment with a known PARP inhibitor

          -  Patient has been diagnosed and/or treated for any invasive cancer (other than study
             disease) less than 5 years prior to study enrollment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Geneva</city>
        <state>Illinois</state>
        <zip>60134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warrenville</city>
        <state>Illinois</state>
        <zip>60555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215-5271</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620-4159</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Libramont</city>
        <zip>6800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plzen-Lochotin</city>
        <zip>30460</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Prague</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Prague</city>
        <zip>128 51</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oulu</city>
        <zip>90029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Caen Cedex 05</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nice Cedex 2</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pierre-Benite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rennes Cedex</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karlsruhe</city>
        <state>Baden-Wuerttemberg</state>
        <zip>76135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schwaebisch Hall</city>
        <state>Baden-Wuerttemberg</state>
        <zip>74523</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fuerth</city>
        <state>Bayern</state>
        <zip>90766</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goettingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hildesheim</city>
        <state>Niedersachsen</state>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ludwigshafen</city>
        <state>Rheinland-Pfalz</state>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Galway</city>
        <zip>H91 YR71</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wilton, Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Meldola (FC)</city>
        <state>Emilia-Romagna</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Candiolo (TO)</city>
        <state>Piemonte</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lecce</city>
        <state>Puglia</state>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mirano</city>
        <state>Veneto</state>
        <zip>30035</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irkutsk</city>
        <zip>664035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ivanovo</city>
        <zip>153040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660133</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orenburg</city>
        <zip>460021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>194017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elche</city>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hospitalet de Llobregat, Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Sebasti√°n</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frauenfeld</city>
        <zip>8501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dnipro</city>
        <zip>49100</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kherson</city>
        <zip>73000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krivoy Rog</city>
        <zip>50048</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vinnitsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69040</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portsmouth</city>
        <state>Hampshire</state>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bath</city>
        <state>Somerset</state>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stoke-on-Trent</city>
        <state>Staffordshire</state>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Blackburn</city>
        <zip>BB2 3HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gonz√°lez-Mart√≠n A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-P√©rez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.</citation>
    <PMID>31562799</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <results_first_submitted>May 4, 2020</results_first_submitted>
  <results_first_submitted_qc>June 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2020</results_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>PARP Inhibitor</keyword>
  <keyword>HRD</keyword>
  <keyword>HRD positive</keyword>
  <keyword>PRIMA</keyword>
  <keyword>PRIMA Clinical Trial</keyword>
  <keyword>PRIMA Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niraparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02655016/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02655016/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In this double-blind, randomized, placebo-controlled study, participants with stage III or IV ovarian cancer were randomized to receive either niraparib or placebo in 2:1 ratio. The results presented are based on the primary analysis up to month 34. Data collection is still on-going and additional results will be provided after study completion.</recruitment_details>
      <pre_assignment_details>A total of 989 participants were screened, of which 256 participants did not meet eligibility criteria. A total of 733 participants were enrolled and randomized in the study, of which 728 participants received study treatment (4 participants were screen failures after randomization and 1 participant withdrew consent before first dose).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo matching niraparib 300 milligram (mg) (3√ó100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kilogram [kg] and Baseline platelet count &gt;=150,000 per microliter [ŒºL]) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
        </group>
        <group group_id="P2">
          <title>Niraparib</title>
          <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="487"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="244">2 participants never received treatment due to screen failure after randomization.</participants>
                <participants group_id="P2" count="484">3 participants never received treatment (2 failed screening &amp; 1 withdrew consent before first dose).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ongoing With Treatment in the Study</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="191">69 participants are ongoing in the study.</participants>
                <participants group_id="P2" count="397">177 participants are ongoing in the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site closed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics were presented for all randomized participants including 5 randomized participants who never received treatment (4-Screen failure and 1-Withdrew consent).</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo matching niraparib 300 milligram (mg) (3√ó100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kilogram [kg] and Baseline platelet count &gt;=150,000 per microliter [ŒºL]) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
        </group>
        <group group_id="B2">
          <title>Niraparib</title>
          <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="246"/>
            <count group_id="B2" value="487"/>
            <count group_id="B3" value="733"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="10.39"/>
                    <measurement group_id="B2" value="61.1" spread="10.79"/>
                    <measurement group_id="B3" value="61.2" spread="10.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="246"/>
                    <measurement group_id="B2" value="487"/>
                    <measurement group_id="B3" value="733"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="436"/>
                    <measurement group_id="B3" value="655"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>Progression free survival was defined as the time from the date of treatment randomization to the date of first documentation of disease progression or death due to any cause in the absence of documented progression, whichever occurs first. It was assessed by the blinded independent central review (BICR). Median and 95% confidence interval (CI) are presented.</description>
        <time_frame>Up to 34 months</time_frame>
        <population>Intent-to-Treat (ITT) population comprised of all participants who were randomized into the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching niraparib 300 milligram (mg) (3√ó100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kilogram [kg] and Baseline platelet count &gt;=150,000 per microliter [ŒºL]) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
          <group group_id="O2">
            <title>Niraparib</title>
            <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Progression free survival was defined as the time from the date of treatment randomization to the date of first documentation of disease progression or death due to any cause in the absence of documented progression, whichever occurs first. It was assessed by the blinded independent central review (BICR). Median and 95% confidence interval (CI) are presented.</description>
          <population>Intent-to-Treat (ITT) population comprised of all participants who were randomized into the study.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="7.3" upper_limit="8.5"/>
                    <measurement group_id="O2" value="13.8" lower_limit="11.5" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value was calculated based on stratified log-rank test using randomization stratification factors: administration of neoadjuvant chemotherapy, best response to platinum therapy and homologous recombination deficiency (HRD) status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.502</ci_lower_limit>
            <ci_upper_limit>0.755</ci_upper_limit>
            <estimate_desc>If hazard ratio was found to be &lt;1 then niraparib can be considered as superior to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival was defined as the time from the date of randomization to the date of death by any cause. Median and 95% CI are presented for overall survival interim analysis.</description>
        <time_frame>Up to 34 months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching niraparib 300 milligram (mg) (3√ó100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kilogram [kg] and Baseline platelet count &gt;=150,000 per microliter [ŒºL]) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
          <group group_id="O2">
            <title>Niraparib</title>
            <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival was defined as the time from the date of randomization to the date of death by any cause. Median and 95% CI are presented for overall survival interim analysis.</description>
          <population>ITT Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="25.0" upper_limit="NA">NA indicates median and 95% CI (upper limit) could not be derived, as &lt;50% of participants experienced the event within the treatment arm.</measurement>
                    <measurement group_id="O2" value="30.3" lower_limit="30.3" upper_limit="NA">NA indicates 95% CI (upper limit) could not be derived, as &lt;75% of participants experienced the event within the treatment arm.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1238</p_value>
            <p_value_desc>p-value was calculated based on stratified log-rank test using randomization stratification factors: administration of neoadjuvant chemotherapy, best response to platinum therapy and HRD status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.442</ci_lower_limit>
            <ci_upper_limit>1.106</ci_upper_limit>
            <estimate_desc>If hazard ratio was found to be &lt;1 then niraparib can be considered as superior to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Subsequent Therapy (TFST)</title>
        <description>Time to first subsequent therapy was defined as the time from the date of randomization to the date of the first subsequent anti-cancer therapy or death, whichever occurs first. Median and 95% CI are presented.</description>
        <time_frame>Up to 34 months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching niraparib 300 milligram (mg) (3√ó100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kilogram [kg] and Baseline platelet count &gt;=150,000 per microliter [ŒºL]) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
          <group group_id="O2">
            <title>Niraparib</title>
            <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Subsequent Therapy (TFST)</title>
          <description>Time to first subsequent therapy was defined as the time from the date of randomization to the date of the first subsequent anti-cancer therapy or death, whichever occurs first. Median and 95% CI are presented.</description>
          <population>ITT Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="10.3" upper_limit="13.9"/>
                    <measurement group_id="O2" value="18.6" lower_limit="15.8" upper_limit="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>p-value was calculated based on stratified log-rank test using randomization stratification factors: administration of neoadjuvant chemotherapy, best response to platinum therapy and HRD status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.521</ci_lower_limit>
            <ci_upper_limit>0.802</ci_upper_limit>
            <estimate_desc>If hazard ratio was found to be &lt;1 then niraparib can be considered as superior to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival-2 (PFS2)</title>
        <description>PFS2 was defined as the time from the date of randomization to the date of progression on the next anti-cancer therapy following study treatment or death by any cause, whichever occurs first. Median and 95% CI are presented.</description>
        <time_frame>Up to 34 months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching niraparib 300 milligram (mg) (3√ó100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kilogram [kg] and Baseline platelet count &gt;=150,000 per microliter [ŒºL]) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
          <group group_id="O2">
            <title>Niraparib</title>
            <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival-2 (PFS2)</title>
          <description>PFS2 was defined as the time from the date of randomization to the date of progression on the next anti-cancer therapy following study treatment or death by any cause, whichever occurs first. Median and 95% CI are presented.</description>
          <population>ITT Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">NA indicates median and 95% CI could not be derived, as &lt;25% of participants experienced the event within the treatment arm.</measurement>
                    <measurement group_id="O2" value="27.2" lower_limit="25.3" upper_limit="NA">NA indicates 95% CI (upper limit) could not be derived, as &lt;75% of participants experienced the event within the treatment arm.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2242</p_value>
            <p_value_desc>p-value was calculated based on stratified log-rank test using randomization stratification factors: administration of neoadjuvant chemotherapy, best response to platinum therapy and HRD status.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.577</ci_lower_limit>
            <ci_upper_limit>1.139</ci_upper_limit>
            <estimate_desc>If hazard ratio was found to be &lt;1 then niraparib can be considered as superior to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Participant Reported Outcome (PRO): Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI)</title>
        <description>FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants responded to their symptom experience over the past 7 days using a 5-point Likert scale scored from &quot;not at all&quot; (0) to &quot;very much&quot; (4). FOSI score was calculated as (sum of item scores)*8 divided by (number of items answered). The FOSI score ranged from 0 (severely symptomatic) to 32 (asymptomatic). A higher score indicated a better quality of life (QoL). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
        <time_frame>Baseline (Day 1, Pre-dose) and Up to Week 24</time_frame>
        <population>ITT Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching niraparib 300 milligram (mg) (3√ó100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kilogram [kg] and Baseline platelet count &gt;=150,000 per microliter [ŒºL]) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
          <group group_id="O2">
            <title>Niraparib</title>
            <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participant Reported Outcome (PRO): Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI)</title>
          <description>FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants responded to their symptom experience over the past 7 days using a 5-point Likert scale scored from &quot;not at all&quot; (0) to &quot;very much&quot; (4). FOSI score was calculated as (sum of item scores)*8 divided by (number of items answered). The FOSI score ranged from 0 (severely symptomatic) to 32 (asymptomatic). A higher score indicated a better quality of life (QoL). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
          <population>ITT Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.22"/>
                    <measurement group_id="O2" value="-0.4" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PRO: European Quality of Life Scale, 5-dimensions, 5-levels of Severity (EQ-5D-5L) Utility Score</title>
        <description>The EQ-5D-5L is a well-validated general preference-based, health-related QoL instrument. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
        <time_frame>Baseline (Day 1, Pre-dose) and Up to Week 24</time_frame>
        <population>ITT Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching niraparib 300 milligram (mg) (3√ó100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kilogram [kg] and Baseline platelet count &gt;=150,000 per microliter [ŒºL]) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
          <group group_id="O2">
            <title>Niraparib</title>
            <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PRO: European Quality of Life Scale, 5-dimensions, 5-levels of Severity (EQ-5D-5L) Utility Score</title>
          <description>The EQ-5D-5L is a well-validated general preference-based, health-related QoL instrument. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
          <population>ITT Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" spread="0.0066"/>
                    <measurement group_id="O2" value="0.016" spread="0.0046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Scales of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)</title>
        <description>EORTC-QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale (global health status, QoL), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty) assessing additional symptoms commonly reported by participants with cancer. Five functional scales had total 15 items (physical-5, role-2, cognitive-4, emotional-2, and social-2). Each functional scales score was calculated by averaging scores of all scale items and transforming average scores linearly (1 minus [average score minus 1] divided by 3*100). All of the functional scales range in score from 0 to 100. Higher score represents a higher (&quot;better&quot;) level of functioning. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
        <time_frame>Baseline (Day 1, Pre-dose) and Up to Week 24</time_frame>
        <population>ITT Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching niraparib 300 milligram (mg) (3√ó100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kilogram [kg] and Baseline platelet count &gt;=150,000 per microliter [ŒºL]) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
          <group group_id="O2">
            <title>Niraparib</title>
            <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Scales of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)</title>
          <description>EORTC-QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale (global health status, QoL), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty) assessing additional symptoms commonly reported by participants with cancer. Five functional scales had total 15 items (physical-5, role-2, cognitive-4, emotional-2, and social-2). Each functional scales score was calculated by averaging scores of all scale items and transforming average scores linearly (1 minus [average score minus 1] divided by 3*100). All of the functional scales range in score from 0 to 100. Higher score represents a higher (&quot;better&quot;) level of functioning. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
          <population>ITT Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning, n=244,479</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="479"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.119" spread="0.8131"/>
                    <measurement group_id="O2" value="2.013" spread="0.5735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Functioning, n=244,479</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="479"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.341" spread="1.2427"/>
                    <measurement group_id="O2" value="1.590" spread="0.8810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional Functioning, n=243,478</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.011" spread="1.1218"/>
                    <measurement group_id="O2" value="-0.870" spread="0.7685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive Functioning, n=243,478</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" spread="1.2105"/>
                    <measurement group_id="O2" value="-0.842" spread="0.7952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning, n=243,478</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.557" spread="1.2449"/>
                    <measurement group_id="O2" value="4.445" spread="0.8633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Global Health Status/QoL of EORTC-QLQ-C30</title>
        <description>EORTC-QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale (global health status, QoL), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty) assessing additional symptoms commonly reported by participants with cancer. A global health status/QoL scale had total 2 items. Each global health status/QoL scales score was calculated by averaging scores of all scale items and transforming average scores linearly ([average score minus 1] divided by 6*100). The global health status/QoL scales range in score from 0 to 100. Higher score represents a higher (&quot;better&quot;) level of health status/QoL. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
        <time_frame>Baseline (Day 1, Pre-dose) and Up to Week 24</time_frame>
        <population>ITT Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching niraparib 300 milligram (mg) (3√ó100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kilogram [kg] and Baseline platelet count &gt;=150,000 per microliter [ŒºL]) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
          <group group_id="O2">
            <title>Niraparib</title>
            <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Global Health Status/QoL of EORTC-QLQ-C30</title>
          <description>EORTC-QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale (global health status, QoL), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty) assessing additional symptoms commonly reported by participants with cancer. A global health status/QoL scale had total 2 items. Each global health status/QoL scales score was calculated by averaging scores of all scale items and transforming average scores linearly ([average score minus 1] divided by 6*100). The global health status/QoL scales range in score from 0 to 100. Higher score represents a higher (&quot;better&quot;) level of health status/QoL. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
          <population>ITT Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.177" spread="1.0005"/>
                    <measurement group_id="O2" value="1.009" spread="0.6898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Symptoms Scales and Symptoms Items (Dyspnea, Appetite Loss, Insomnia, Constipation, Diarrhea and Financial Difficulty) of EORTC-QLQ-C30</title>
        <description>EORTC-QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale, and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty) assessing additional symptoms commonly reported by participants with cancer. Symptom scale had total 7 items (fatigue-3, pain-2, nausea/vomiting-2). Each symptoms scales and 6 single additional symptoms items score was calculated by averaging scores of all scale items and transforming average scores linearly ([average score minus 1] divided by 3*100). All of the symptoms scales and 6 single additional symptoms scales range in score from 0 to 100. Higher score represents a higher (&quot;worse&quot;) level of symptoms. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
        <time_frame>Baseline (Day 1, Pre-dose) and Up to Week 24</time_frame>
        <population>ITT Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching niraparib 300 milligram (mg) (3√ó100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kilogram [kg] and Baseline platelet count &gt;=150,000 per microliter [ŒºL]) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
          <group group_id="O2">
            <title>Niraparib</title>
            <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Symptoms Scales and Symptoms Items (Dyspnea, Appetite Loss, Insomnia, Constipation, Diarrhea and Financial Difficulty) of EORTC-QLQ-C30</title>
          <description>EORTC-QLQ-C30 incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale, and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty) assessing additional symptoms commonly reported by participants with cancer. Symptom scale had total 7 items (fatigue-3, pain-2, nausea/vomiting-2). Each symptoms scales and 6 single additional symptoms items score was calculated by averaging scores of all scale items and transforming average scores linearly ([average score minus 1] divided by 3*100). All of the symptoms scales and 6 single additional symptoms scales range in score from 0 to 100. Higher score represents a higher (&quot;worse&quot;) level of symptoms. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
          <population>ITT Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="480"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue, n=243,479</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="479"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.082" spread="1.2394"/>
                    <measurement group_id="O2" value="0.085" spread="0.8363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/Vomiting, n=244,479</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="479"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.673" spread="0.7595"/>
                    <measurement group_id="O2" value="3.115" spread="0.4828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, n=244,480</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="480"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.195" spread="1.2274"/>
                    <measurement group_id="O2" value="0.765" spread="1.0166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea, n=244,479</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="479"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.644" spread="1.3592"/>
                    <measurement group_id="O2" value="1.347" spread="0.8518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia, n=244,479</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="479"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.195" spread="1.9882"/>
                    <measurement group_id="O2" value="3.478" spread="1.2791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite Loss, n=8,30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.827" spread="4.3987"/>
                    <measurement group_id="O2" value="-0.395" spread="2.3195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation, n=244,478</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="478"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.147" spread="1.5793"/>
                    <measurement group_id="O2" value="6.356" spread="1.0446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea, n=8,30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.335" spread="3.8667"/>
                    <measurement group_id="O2" value="-3.340" spread="2.0136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Financial Difficulties, n=243,475</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="475"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.058" spread="1.2978"/>
                    <measurement group_id="O2" value="-3.356" spread="0.9276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Scales of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Ovarian Cancer Module (EORTC-QLQ-OV28)</title>
        <description>EORTC-QLQ-OV28 is supplement to EORTC-QLQ-C30. It includes 3 functional scales (body image, sexuality, attitude to disease/treatment) and 5 symptom scales/items (abdominal/gastrointestinal [GI] symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side-effects, and hair loss). Functional scales score (body Image and attitude to disease/treatment) was calculated by averaging scores of all scale items and transforming average scores linearly (1 minus [average score minus 1] divided by 3*100). Functional scales score (sexuality) was calculated by averaging scores of all scale items and transforming average scores linearly ([average score minus 1] divided by 3*100). All of the functional scales range in score from 0 to 100. Higher score represents a higher (&quot;better&quot;) level of functioning. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
        <time_frame>Baseline (Day 1, Pre-dose) and Up to 34 months</time_frame>
        <population>ITT Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching niraparib 300 milligram (mg) (3√ó100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kilogram [kg] and Baseline platelet count &gt;=150,000 per microliter [ŒºL]) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
          <group group_id="O2">
            <title>Niraparib</title>
            <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Scales of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Ovarian Cancer Module (EORTC-QLQ-OV28)</title>
          <description>EORTC-QLQ-OV28 is supplement to EORTC-QLQ-C30. It includes 3 functional scales (body image, sexuality, attitude to disease/treatment) and 5 symptom scales/items (abdominal/gastrointestinal [GI] symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side-effects, and hair loss). Functional scales score (body Image and attitude to disease/treatment) was calculated by averaging scores of all scale items and transforming average scores linearly (1 minus [average score minus 1] divided by 3*100). Functional scales score (sexuality) was calculated by averaging scores of all scale items and transforming average scores linearly ([average score minus 1] divided by 3*100). All of the functional scales range in score from 0 to 100. Higher score represents a higher (&quot;better&quot;) level of functioning. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
          <population>ITT Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="475"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Body Image, n=244,475</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="475"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.069" spread="1.4820"/>
                    <measurement group_id="O2" value="8.488" spread="1.0138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexuality, n=240,471</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="240"/>
                    <count group_id="O2" value="471"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.257" spread="1.1886"/>
                    <measurement group_id="O2" value="3.625" spread="0.8004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attitude to disease/Treatment, n=244,475</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="475"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.216" spread="1.3257"/>
                    <measurement group_id="O2" value="13.660" spread="0.9309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Symptoms Scale of EORTC-QLQ-OV28</title>
        <description>EORTC-QLQ-OV28 is supplement to EORTC-QLQ-C30. It includes 3 functional scales (body image, sexuality, attitude to disease/treatment) and 5 symptom scales/items (abdominal/GI symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side-effects, and hair loss). Symptoms scales score was calculated by averaging scores of all scale items and transforming average scores linearly ([average score minus 1] divided by 3*100). All of the symptoms scales range in score from 0 to 100. Higher score represents a higher (&quot;worse&quot;) level of symptoms. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
        <time_frame>Baseline (Day 1, Pre-dose) and Up to 34 months</time_frame>
        <population>ITT Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching niraparib 300 milligram (mg) (3√ó100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kilogram [kg] and Baseline platelet count &gt;=150,000 per microliter [ŒºL]) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
          <group group_id="O2">
            <title>Niraparib</title>
            <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Symptoms Scale of EORTC-QLQ-OV28</title>
          <description>EORTC-QLQ-OV28 is supplement to EORTC-QLQ-C30. It includes 3 functional scales (body image, sexuality, attitude to disease/treatment) and 5 symptom scales/items (abdominal/GI symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side-effects, and hair loss). Symptoms scales score was calculated by averaging scores of all scale items and transforming average scores linearly ([average score minus 1] divided by 3*100). All of the symptoms scales range in score from 0 to 100. Higher score represents a higher (&quot;worse&quot;) level of symptoms. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).</description>
          <population>ITT Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="481"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdominal/GI, n=244,481</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="481"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.832" spread="0.8110"/>
                    <measurement group_id="O2" value="2.185" spread="0.5703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral Neuropathy, n=244,480</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="480"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.629" spread="1.3219"/>
                    <measurement group_id="O2" value="-8.217" spread="0.9295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hormonal/Menopausal Symptoms, n=244,480</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="480"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.521" spread="1.3074"/>
                    <measurement group_id="O2" value="1.501" spread="0.8803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Chemotherapy Side Effects, n=244,480</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="480"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.023" spread="0.8358"/>
                    <measurement group_id="O2" value="-2.219" spread="0.5581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hair Loss, n=242,477</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="242"/>
                    <count group_id="O2" value="477"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.743" spread="1.3690"/>
                    <measurement group_id="O2" value="-23.363" spread="0.9821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Any Non-serious Adverse Event (Non-SAE) or Any SAE</title>
        <description>An adverse event is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.</description>
        <time_frame>Up to 34 months</time_frame>
        <population>Safety Population comprised of all participants who received at least 1 dose of study drug. 5 participants (2 participants from Placebo group and 3 participants from Niraparib group) out of 733 participants did not receive any study treatment and thus, were excluded from the Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching niraparib 300 milligram (mg) (3√ó100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kilogram [kg] and Baseline platelet count &gt;=150,000 per microliter [ŒºL]) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
          <group group_id="O2">
            <title>Niraparib</title>
            <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Non-serious Adverse Event (Non-SAE) or Any SAE</title>
          <description>An adverse event is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.</description>
          <population>Safety Population comprised of all participants who received at least 1 dose of study drug. 5 participants (2 participants from Placebo group and 3 participants from Niraparib group) out of 733 participants did not receive any study treatment and thus, were excluded from the Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="484"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any non-SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223"/>
                    <measurement group_id="O2" value="478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Curve (AUC) From 0 to the Last Quantifiable Concentration (AUC[0-last])</title>
        <description>Blood samples were planned to be collected for assessment of AUC(0-last).</description>
        <time_frame>Up to 34 months</time_frame>
        <population>ITT Population. This was an other pre-specified outcome measure. Data will not be analyzed and reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Niraparib</title>
            <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) From 0 to the Last Quantifiable Concentration (AUC[0-last])</title>
          <description>Blood samples were planned to be collected for assessment of AUC(0-last).</description>
          <population>ITT Population. This was an other pre-specified outcome measure. Data will not be analyzed and reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Peak Plasma Concentration (Cmax)</title>
        <description>Blood samples were planned to be collected for assessment of Cmax.</description>
        <time_frame>Up to 34 months</time_frame>
        <population>ITT Population. This was an other pre-specified outcome measure. Data will not be analyzed and reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Niraparib</title>
            <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax)</title>
          <description>Blood samples were planned to be collected for assessment of Cmax.</description>
          <population>ITT Population. This was an other pre-specified outcome measure. Data will not be analyzed and reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Positive HRD Test</title>
        <description>Number of participants with positive HRD test was planned to be assessed.</description>
        <time_frame>Up to 34 months</time_frame>
        <population>ITT Population. This was an other pre-specified outcome measure. Data will not be analyzed and reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matching niraparib 300 milligram (mg) (3√ó100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kilogram [kg] and Baseline platelet count &gt;=150,000 per microliter [ŒºL]) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
          <group group_id="O2">
            <title>Niraparib</title>
            <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive HRD Test</title>
          <description>Number of participants with positive HRD test was planned to be assessed.</description>
          <population>ITT Population. This was an other pre-specified outcome measure. Data will not be analyzed and reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and non-SAEs were reported from start of study treatment (Day 1) and up to month 34 (primary analysis)</time_frame>
      <desc>Non-SAEs and SAEs were presented for Safety Population. 5 participants out of 733 participants did not receive any study treatment and thus, were excluded from the Safety Population. The results presented are based on the primary analysis up to month 34. Data collection is still on-going and additional results will be provided after study completion.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo matching niraparib 300 milligram (mg) (3√ó100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kilogram [kg] and Baseline platelet count &gt;=150,000 per microliter [ŒºL]) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
        </group>
        <group group_id="E2">
          <title>Niraparib</title>
          <description>Participants received niraparib 300 mg (3√ó100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant‚Äôs Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3√ó100 mg capsules for participants with a Baseline body weight &gt;=77 kg and Baseline platelet count &gt;=150,000 per ŒºL) or 200 mg (2√ó100 mg capsules for participants with a Baseline body weight &lt;77 kg or Baseline platelet count &lt;150,000 per ŒºL).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="156" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="28" subjects_affected="27" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="65" subjects_affected="59" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal fat apron</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="244"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Infected lymphocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Postoperative hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="25" subjects_affected="20" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Metastases to breast</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Fasting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="223" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="478" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="83" subjects_affected="43" subjects_at_risk="244"/>
                <counts group_id="E2" events="921" subjects_affected="306" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Haemorrhagic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="13" subjects_at_risk="244"/>
                <counts group_id="E2" events="145" subjects_affected="57" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="40" subjects_affected="12" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Macrocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="16" subjects_at_risk="244"/>
                <counts group_id="E2" events="366" subjects_affected="126" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="244"/>
                <counts group_id="E2" events="549" subjects_affected="210" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Metabolic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="244"/>
                <counts group_id="E2" events="45" subjects_affected="39" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ear congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ear haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Excessive cerumen production</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>External ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Paraesthesia ear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Thyroid cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Cataract nuclear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Eye oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Eyelid sensory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypermetropia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Myopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Retinal exudates</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Scleral disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="244"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="36" subjects_affected="30" subjects_at_risk="244"/>
                <counts group_id="E2" events="36" subjects_affected="32" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="102" subjects_affected="74" subjects_at_risk="244"/>
                <counts group_id="E2" events="146" subjects_affected="105" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="244"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="26" subjects_affected="21" subjects_at_risk="244"/>
                <counts group_id="E2" events="59" subjects_affected="41" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Aerophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Anal incontinence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Anal pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="52" subjects_affected="46" subjects_at_risk="244"/>
                <counts group_id="E2" events="262" subjects_affected="189" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Defaecation urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="82" subjects_affected="55" subjects_at_risk="244"/>
                <counts group_id="E2" events="132" subjects_affected="91" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E2" events="46" subjects_affected="40" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="244"/>
                <counts group_id="E2" events="43" subjects_affected="34" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="244"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gastric disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gastrointestinal sounds abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="244"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Intestinal mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Lip blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Lip disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="100" subjects_affected="67" subjects_at_risk="244"/>
                <counts group_id="E2" events="448" subjects_affected="278" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Noninfective gingivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Oral contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Oral dysaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Oral mucosal blistering</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Oral mucosal discolouration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pancreatic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Rectal discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Rectal tenesmus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Salivary duct stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tongue coated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tooth impacted</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="34" subjects_affected="28" subjects_at_risk="244"/>
                <counts group_id="E2" events="153" subjects_affected="108" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adhesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="47" subjects_affected="31" subjects_at_risk="244"/>
                <counts group_id="E2" events="138" subjects_affected="78" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Catheter site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Catheter site rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Catheter site vesicles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Early satiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="101" subjects_affected="72" subjects_at_risk="244"/>
                <counts group_id="E2" events="242" subjects_affected="168" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hernia pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="244"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Mucosal dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E2" events="29" subjects_affected="23" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="19" subjects_affected="11" subjects_at_risk="244"/>
                <counts group_id="E2" events="35" subjects_affected="30" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="244"/>
                <counts group_id="E2" events="47" subjects_affected="41" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Secretion discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Sensation of foreign body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Suprapubic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Unevaluable event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="8" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypertransaminasaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Angular cheilitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Catheter site cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gastric infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gastrointestinal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="244"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Medical device site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Shigella infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="244"/>
                <counts group_id="E2" events="27" subjects_affected="15" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="244"/>
                <counts group_id="E2" events="31" subjects_affected="28" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="244"/>
                <counts group_id="E2" events="48" subjects_affected="44" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="40" subjects_affected="25" subjects_at_risk="244"/>
                <counts group_id="E2" events="55" subjects_affected="49" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vulvitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Allergic transfusion reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Bone contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="29" subjects_affected="22" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Incision site swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Mallet finger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Postoperative hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Stoma complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Stoma site discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Stoma site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Stoma site inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vaccination complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vascular access malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Wound evisceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="244"/>
                <counts group_id="E2" events="67" subjects_affected="42" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="244"/>
                <counts group_id="E2" events="78" subjects_affected="43" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E2" events="66" subjects_affected="42" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="13" subjects_affected="7" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blood chloride increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="244"/>
                <counts group_id="E2" events="96" subjects_affected="55" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Bone density decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Carbohydrate antigen 125 increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="244"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Eosinophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="21" subjects_affected="11" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="43" subjects_affected="25" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Mean cell volume increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Monocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Monocyte count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="244"/>
                <counts group_id="E2" events="207" subjects_affected="82" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="338" subjects_affected="129" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Protein total decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Sputum abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vitamin D decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="27" subjects_affected="20" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="30" subjects_affected="19" subjects_at_risk="244"/>
                <counts group_id="E2" events="24" subjects_affected="17" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="8" subjects_at_risk="244"/>
                <counts group_id="E2" events="205" subjects_affected="74" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Cell death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="244"/>
                <counts group_id="E2" events="112" subjects_affected="92" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hyperalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E2" events="28" subjects_affected="19" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypermagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hyperproteinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypochloraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="37" subjects_affected="25" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="244"/>
                <counts group_id="E2" events="58" subjects_affected="38" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="35" subjects_affected="19" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="10" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Magnesium deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="77" subjects_affected="47" subjects_at_risk="244"/>
                <counts group_id="E2" events="116" subjects_affected="85" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="244"/>
                <counts group_id="E2" events="84" subjects_affected="64" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Bone disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Bone lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Bone swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Extremity contracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypercreatinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Joint instability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Muscle fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="25" subjects_affected="14" subjects_at_risk="244"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="244"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="244"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="244"/>
                <counts group_id="E2" events="49" subjects_affected="36" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Myalgia intercostal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="244"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="244"/>
                <counts group_id="E2" events="53" subjects_affected="38" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Scleroderma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Soft tissue disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tendon pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tenosynovitis stenosans</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acrochordon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Invasive breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vaginal neoplasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Aura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="30" subjects_affected="26" subjects_at_risk="244"/>
                <counts group_id="E2" events="96" subjects_affected="71" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="244"/>
                <counts group_id="E2" events="34" subjects_affected="25" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Facial nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="46" subjects_affected="36" subjects_at_risk="244"/>
                <counts group_id="E2" events="190" subjects_affected="126" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="244"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="244"/>
                <counts group_id="E2" events="38" subjects_affected="31" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="244"/>
                <counts group_id="E2" events="20" subjects_affected="11" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="244"/>
                <counts group_id="E2" events="21" subjects_affected="18" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="244"/>
                <counts group_id="E2" events="53" subjects_affected="43" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="244"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Genito-pelvic pain/penetration disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hallucination, olfactory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="35" subjects_at_risk="244"/>
                <counts group_id="E2" events="162" subjects_affected="119" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Libido increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Bladder discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Cystitis interstitial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="244"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="244"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Urinary tract pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Atrophic vulvovaginitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Breast calcifications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Breast discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Coital bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dyspareunia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Genital paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Genital swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Menopausal symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Perineal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vaginal mucosal blistering</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vulvovaginal burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vulvovaginal dryness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="244"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="45" subjects_affected="35" subjects_at_risk="244"/>
                <counts group_id="E2" events="92" subjects_affected="74" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="244"/>
                <counts group_id="E2" events="129" subjects_affected="88" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dyspnoea at rest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="244"/>
                <counts group_id="E2" events="28" subjects_affected="21" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Nasal pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Oropharyngeal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="244"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Painful respiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Paranasal sinus discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tonsillar disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="244"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Blood blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="244"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Erythema dyschromicum perstans</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hair texture abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hirsutism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypertrichosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Ingrown hair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Macule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Madarosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Nail discolouration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Nail growth abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Nail ridging</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Onychomadesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="35" subjects_affected="29" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pityriasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="244"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="244"/>
                <counts group_id="E2" events="29" subjects_affected="23" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="244"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Scar pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Sebaceous gland disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Skin reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Solar dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Solar lentigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Astringent therapy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Blood pressure fluctuation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="244"/>
                <counts group_id="E2" events="64" subjects_affected="54" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="28" subjects_affected="17" subjects_at_risk="244"/>
                <counts group_id="E2" events="142" subjects_affected="81" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="484"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="484"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

